Answers are grounded in this paper and cite their sources.
Single-center experience describes changes in hearing, quality of life, and tumor volume after bevacizumab protocol implementation in NF2.
To describe the evolution of hearing parameters, quality of life, and vestibular schwannoma (VS) volume in patients with NF2-related schwannomatosis (NF2) before and after the implementation of a standardized protocol for disease surveillance bevacizumab administration.
No takes yet. Share an insight, caveat, or question.
Greciet et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: